๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with non-small-cell lung carcinoma

โœ Scribed by Takenori Niioka; Tsukasa Uno; Norio Yasui-Furukori; Takenori Takahata; Mikiko Shimizu; Kazunobu Sugawara; Tomonori Tateishi

Publisher
Springer
Year
2006
Tongue
English
Weight
184 KB
Volume
59
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Pharmacokinetics of unchanged carboplati
Pharmacokinetics of unchanged carboplatin (CBDCA) in patients with small cell lung carcinoma
โœ Phillip A. Reece; James F. Bishop; Ian N. Olver; Irene Stafford; Brian L. Hilloc ๐Ÿ“‚ Article ๐Ÿ“… 1987 ๐Ÿ› Springer ๐ŸŒ English โš– 476 KB

The disposition of the cisplatin analogue carboplatin was studied in seven patients with small cell lung cancer. Carboplatin 100 mg/m2 was administered without hydration by a 1-h infusion with VP16-213 120 mg/m2 on days 1, 2 and 3 of each course. Plasma and urine collections were made on days 1 and

Therapeutic efficacy and pharmacokinetic
Therapeutic efficacy and pharmacokinetics of vindesine and vindesine-cisplatin in previously treated patients with non-small cell lung carcinoma
โœ Joachim Z. Fuks; Merrill J. Egorin; Joseph Aisner; David A. Echo; Stanley Ostrow ๐Ÿ“‚ Article ๐Ÿ“… 1983 ๐Ÿ› Springer ๐ŸŒ English โš– 480 KB

Twenty-nine patients with non-small cell lung cancer refractory to prior therapy were treated with either vindesine (VDS) alone (3 mg/m2 every week) or the combination of VDS plus cisplatin (DDP) (100 mg/m2 every 28 days). Serial blood and urine samples were collected to assess the pharmacokinetics